Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO
Novartis, one of the world’s biggest spenders on drug R&D, will soon be run by a development expert.
The pharma giant announced Monday morning that Joe Jimenez is stepping down in February and handing the reins over to 41-year-old Vas Narasimhan, an exuberant advocate of cutting-edge science who’s been making his mark with a slate of successful programs for the company’s next wave of blockbuster drugs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.